Pamidronic acid
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| |
| Pamidronic acid
| |
| Systematic (IUPAC) name | |
| (3-amino-1-hydroxy-1-phosphono-propyl)phosphonic acid | |
| Identifiers | |
| CAS number | |
| ATC code | M05 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C3H11NO7P2 |
| Mol. mass | 235.07 g/mol |
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Protein binding | 54% |
| Metabolism | Nil |
| Half life | 28 ± 7 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Intravenous |
|
WikiDoc Resources for Pamidronic acid | |
|
Articles | |
|---|---|
|
Most recent articles on Pamidronic acid Most cited articles on Pamidronic acid | |
|
Media | |
|
Powerpoint slides on Pamidronic acid | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Pamidronic acid at Clinical Trials.gov Trial results on Pamidronic acid Clinical Trials on Pamidronic acid at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Pamidronic acid NICE Guidance on Pamidronic acid
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Pamidronic acid Discussion groups on Pamidronic acid Patient Handouts on Pamidronic acid Directions to Hospitals Treating Pamidronic acid Risk calculators and risk factors for Pamidronic acid
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Pamidronic acid | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Pamidronic acid (INN) or pamidronate disodium (USAN), marketed as pamidronate disodium pentahydrate under the brand name Aredia®, is a bisphosphonate.
Uses
It is used to prevent bone loss, and treat osteoporosis. It is also used to strengthen bone in Paget's disease, to prevent bone loss due to steroid use, and in certain cancers with high propensity to bone, such as multiple myeloma. In multiple myeloma, it is usually administered as an intravenous infusion, lasting about 3 hours. The therapy is repeated monthly, and lasts for the life of the patient. Due to its ability to sequester calcium in bone, it is also used to treat high calcium levels.
Administration
Intravenous, usually 90 mg monthly. 30 mg, 60 mg, and 90 mg vials are available, mixed with mannitol.
Side effects
Common side effects include bone pain, low calcium levels, nausea, and dizziness. Osteonecrosis of the jaw is a rare complication which has been associated with the use of bisphosphonates, including pamidronate.[1]
Pamidronate activates human γδ T cells in vitro and in vivo, which may lead to flu-like symptoms upon administration.
References
Drugs for treatment of bone diseases (M05) | |
|---|---|
| Bisphosphonates | Nitrogenous (Pamidronic acid, Alendronic acid, Ibandronic acid, Risedronic acid, Zoledronic acid) - Non-nitrogenous (Etidronic acid, Clodronic acid, Tiludronic acid) |
| Bone morphogenetic proteins | Dibotermin alfa - Eptotermin alfa |
| Other | Ipriflavone - Aluminium chlorohydrate - Strontium ranelate |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
